By Chris Wack
Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis.
The discontinuation follows a prespecified data review and recommendation by an independent Data Safety Monitoring Board, as well as a secondary review and recommendation by an outside expert panel.
The late-stage biopharmaceutical company said that while an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups led to the discontinuation of the trial, early evidence of efficacy on the forced vital capacity endpoint was also observed.
Overall, the percentage of IPF-related adverse events in both dose groups was comparable--about 10%.
The company plans to analyze the complete data from the trial and evaluate next steps for bexotegrast's development, including additional dose-ranging Phase 2b studies with lower doses in pulmonary fibrosis.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 03, 2025 09:47 ET (14:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。